Early development of the metabolic syndrome after chemotherapy for testicular cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic syndrome (MS) might increase the risk of cardiovascular disease in testicular cancer (TC) survivors. We investigated its prevalence, development, vascular implications, and the role of gonadal function. METHODS: TC survivors treated with chemotherapy and follow-up ≥3 years (N = 370, study I) were retrospectively evaluated for the development of cardiovascular risk factors. A subgroup followed 3-20 years (N = 173, study II) was compared with controls (N = 1085) for MS prevalence and evaluated for vascular function. RESULTS: In TC survivors (study I), 24% developed overweight, 24% hypercholesterolemia, and 30% hypertension, after median follow-up of 1.7, 0.9, and 5.1 years, respectively. At the median follow-up of 5 years (study II), 25% of survivors have the MS {odds ratio (OR) 2.2, [95% confidence interval (CI) 1.5-3.3] compared with controls}. Survivors with MS have features of inflammation and prothrombotic state, increased carotid artery intima-media thickness. Survivors with testosterone levels <15 nmol/l (22%) have an increased risk of the MS (OR 4.1, 95% CI 1.8-9.3). CONCLUSIONS: The current data suggest that the MS occurs at earlier age in TC survivors treated with chemotherapy compared with controls and is accompanied by early signs of atherosclerosis. As low testosterone may have a causal role, it is a target for interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 1×
“In addition, visceral adipose tissue produces proinflammatory and prothrombotic factors [6, 7].”
BackgroundOverweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 1×
“On the other hand, the MS is increasingly recognized as risk factors for the development of several cancer types [17] and may be consequently overrepresented in patients with cancer.”
BackgroundLorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M., & Sitzer, M. (2007) · Circulation · doi:10.1161/circulationaha.106.628875 · Cited by 2,977
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920
Kupelian, V., Page, S. T., Araujo, A. B., Travison, T. G., Bremner, W. J., & McKinlay, J. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1326 · Cited by 561
Yeap, B. B., Chubb, S. A. P., Hyde, Z., Jamrozik, K., Hankey, G. J., Flicker, L., & Norman, P. E. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0348 · Cited by 128 · cited 1×
“This corresponds with the independent association of low to normal testosterone levels with insulin resistance, as observed in older men [23].”
Background
Cited by
Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claßen, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds579 · Cited by 320
Self-citationOldenburg, J., Fosså, S. D., Nuver, J., Heidenreich, A., Schmoll, H.-J., Bokemeyer, C., Horwich, A., Beyer, J., & Kataja, V. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt304 · Cited by 282
Ormel, H. L., van der Schoot, G. G. F., Sluiter, W. J., Jalving, M., Gietema, J. A., & Walenkamp, A. M. E. (2018) · Psycho-Oncology · doi:10.1002/pon.4612 · Cited by 261
Self-citationCardiovascular disease after cancer therapy
Aleman, B. M. P., Moser, E. C., Nuver, J., Suter, T. M., Maraldo, M. V., Specht, L., Vrieling, C., & Darby, S. C. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.03.002 · Cited by 168
Early ageing after cytotoxic treatment for testicular cancer and cellular senescence: Time to act
Lubberts, S., Meijer, C., Demaria, M., & Gietema, J. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102963 · Cited by 19
“Approximately 25 % of TC survivors after chemotherapy have metabolic syndrome at a median age of 40 years (Nuver et al., 2005; de Haas et al., 2013; Haugnes et al., 2007) (Table 1).”
BackgroundSelf-citation
Metadata
- Authors
- de Haas, E. C., Altena, R., Boezen, H. M., Zwart, N., Smit, A. J., Bakker, S. J. L., van Roon, A. M., Postma, A., Wolffenbuttel, B. H. R., Hoekstra, H. J., van Leeuwen, F. E., Sleijfer, D. T., & Gietema, J. A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 24
- Issue
- 3
- Pages
- 749-755
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2096262742
- Cited by
- 113
- References
- 7
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early development of the metabolic syndrome after chemotherapy for testicular cancer. https://app.cochat.ai/papers/10.1093/annonc/mds527
- The paper
- de Haas, E. C., Altena, R., Boezen, H. M., Zwart, N., Smit, A. J., Bakker, S. J. L., van Roon, A. M., Postma, A., Wolffenbuttel, B. H. R., Hoekstra, H. J., van Leeuwen, F. E., Sleijfer, D. T., & Gietema, J. A. (2013). Early development of the metabolic syndrome after chemotherapy for testicular cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mds527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.